HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scharre, D. W. Articles by Beversdorf, D. Q. Search for Related Content PubMed PubMed Citation Articles by Scharre, D. W. Articles by Beversdorf, D. Q.

A Pilot Open-Label Trial of Citalopram for Restless Activity and Aberrant Motor Behaviors in Alzheimer Disease

Received August 6, 2002; revised October 22, 2002, February 28, 2003; accepted March 11, 2003. From the Division of Cognitive Neurology, Department of Neurology, The Ohio State University, Columbus, OH. Address correspondence to Dr. Scharre, Department of Neurology, 471 Means Hall, 1654 Upham Dr., Columbus, Ohio 43210. e-mail: scharre.1{at}osu.edu

Objective: In a prospective, open-label pilot study in probable-Alzheimer disease (AD) outpatients, the authors investigated the efficacy of citalopram to reduce restless activity and aberrant motor behaviors. Methods: Nineteen subjects were evaluated with Neuropsychiatric Inventory subscale and total scores. Results: There was a significant decline in aberrant motor behaviors and overall behavior problems at 4, 8, and 12 weeks. Conclusion: This study provides initial evidence that citalopram may be effective in reducing aberrant motor behaviors in AD. However, because of the potential biases of an open-label study, these findings need to be confirmed in a larger, controlled trial.

Key Words: Alzheimer Disease Treatment • Citalopram • Motor Disturbances